A citation-based method for searching scientific literature

Robert Kralovics, Francesco Passamonti, Andreas S Buser, Soon-Siong Teo, Ralph Tiedt, Jakob R Passweg, Andre Tichelli, Mario Cazzola, Radek C Skoda. N Engl J Med 2005
Times Cited: 2639







List of co-cited articles
916 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
E Joanna Baxter, Linda M Scott, Peter J Campbell, Clare East, Nasios Fourouclas, Soheila Swanton, George S Vassiliou, Anthony J Bench, Elaine M Boyd, Natasha Curtin,[...]. Lancet 2005
58

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Ross L Levine, Martha Wadleigh, Jan Cools, Benjamin L Ebert, Gerlinde Wernig, Brian J P Huntly, Titus J Boggon, Iwona Wlodarska, Jennifer J Clark, Sandra Moore,[...]. Cancer Cell 2005
56

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.
Chloé James, Valérie Ugo, Jean-Pierre Le Couédic, Judith Staerk, François Delhommeau, Catherine Lacout, Loïc Garçon, Hana Raslova, Roland Berger, Annelise Bennaceur-Griscelli,[...]. Nature 2005
55

Somatic mutations of calreticulin in myeloproliferative neoplasms.
Thorsten Klampfl, Heinz Gisslinger, Ashot S Harutyunyan, Harini Nivarthi, Elisa Rumi, Jelena D Milosevic, Nicole C C Them, Tiina Berg, Bettina Gisslinger, Daniela Pietra,[...]. N Engl J Med 2013
39

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Daniel A Arber, Attilio Orazi, Robert Hasserjian, Jürgen Thiele, Michael J Borowitz, Michelle M Le Beau, Clara D Bloomfield, Mario Cazzola, James W Vardiman. Blood 2016
37

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.
J Nangalia, C E Massie, E J Baxter, F L Nice, G Gundem, D C Wedge, E Avezov, J Li, K Kollmann, D G Kent,[...]. N Engl J Med 2013
34

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Yana Pikman, Benjamin H Lee, Thomas Mercher, Elizabeth McDowell, Benjamin L Ebert, Maricel Gozo, Adam Cuker, Gerlinde Wernig, Sandra Moore, Ilene Galinsky,[...]. PLoS Med 2006
28


JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Linda M Scott, Wei Tong, Ross L Levine, Mike A Scott, Philip A Beer, Michael R Stratton, P Andrew Futreal, Wendy N Erber, Mary Frances McMullin, Claire N Harrison,[...]. N Engl J Med 2007
899
21

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, Richard S Levy, Vikas Gupta, John F DiPersio, John V Catalano, Michael Deininger, Carole Miller, Richard T Silver,[...]. N Engl J Med 2012
17

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.
Animesh D Pardanani, Ross L Levine, Terra Lasho, Yana Pikman, Ruben A Mesa, Martha Wadleigh, David P Steensma, Michelle A Elliott, Alexandra P Wolanskyj, William J Hogan,[...]. Blood 2006
767
17

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Claire Harrison, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Heinz Gisslinger, Roger Waltzman, Viktoriya Stalbovskaya, Mari McQuitty, Deborah S Hunter, Richard Levy, Laurent Knoops,[...]. N Engl J Med 2012
15

Classification and Personalized Prognosis in Myeloproliferative Neoplasms.
Jacob Grinfeld, Jyoti Nangalia, E Joanna Baxter, David C Wedge, Nicos Angelopoulos, Robert Cantrill, Anna L Godfrey, Elli Papaemmanuil, Gunes Gundem, Cathy MacLean,[...]. N Engl J Med 2018
297
15

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.
Ayalew Tefferi, Paola Guglielmelli, Dirk R Larson, Christy Finke, Emnet A Wassie, Lisa Pieri, Naseema Gangat, Rajmonda Fjerza, Alem A Belachew, Terra L Lasho,[...]. Blood 2014
419
15

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
Alessandro M Vannucchi, Jean Jacques Kiladjian, Martin Griesshammer, Tamas Masszi, Simon Durrant, Francesco Passamonti, Claire N Harrison, Fabrizio Pane, Pierre Zachee, Ruben Mesa,[...]. N Engl J Med 2015
511
14

Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease.
Siddhartha Jaiswal, Pradeep Natarajan, Alexander J Silver, Christopher J Gibson, Alexander G Bick, Eugenia Shvartz, Marie McConkey, Namrata Gupta, Stacey Gabriel, Diego Ardissino,[...]. N Engl J Med 2017
14

Age-related clonal hematopoiesis associated with adverse outcomes.
Siddhartha Jaiswal, Pierre Fontanillas, Jason Flannick, Alisa Manning, Peter V Grauman, Brenton G Mar, R Coleman Lindsley, Craig H Mermel, Noel Burtt, Alejandro Chavez,[...]. N Engl J Med 2014
14

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.
Pontus Lundberg, Axel Karow, Ronny Nienhold, Renate Looser, Hui Hao-Shen, Ina Nissen, Sabine Girsberger, Thomas Lehmann, Jakob Passweg, Martin Stern,[...]. Blood 2014
415
14

Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.
Giulio Genovese, Anna K Kähler, Robert E Handsaker, Johan Lindberg, Samuel A Rose, Samuel F Bakhoum, Kimberly Chambert, Eran Mick, Benjamin M Neale, Menachem Fromer,[...]. N Engl J Med 2014
13

Effect of mutation order on myeloproliferative neoplasms.
Christina A Ortmann, David G Kent, Jyoti Nangalia, Yvonne Silber, David C Wedge, Jacob Grinfeld, E Joanna Baxter, Charles E Massie, Elli Papaemmanuil, Suraj Menon,[...]. N Engl J Med 2015
334
12

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
Animesh Pardanani, Claire Harrison, Jorge E Cortes, Francisco Cervantes, Ruben A Mesa, Donald Milligan, Tamás Masszi, Elena Mishchenko, Eric Jourdan, Alessandro M Vannucchi,[...]. JAMA Oncol 2015
257
11

Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
Ilyas Chachoua, Christian Pecquet, Mira El-Khoury, Harini Nivarthi, Roxana-Irina Albu, Caroline Marty, Vitalina Gryshkova, Jean-Philippe Defour, Gaëlle Vertenoeil, Anna Ngo,[...]. Blood 2016
217
10

Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.
Shannon Elf, Nouran S Abdelfattah, Edwin Chen, Javier Perales-Patón, Emily A Rosen, Amy Ko, Fabian Peisker, Natalie Florescu, Silvia Giannini, Ofir Wolach,[...]. Cancer Discov 2016
176
10

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.
C N Harrison, A M Vannucchi, J-J Kiladjian, H K Al-Ali, H Gisslinger, L Knoops, F Cervantes, M M Jones, K Sun, M McQuitty,[...]. Leukemia 2016
287
10

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
James W Vardiman, Jüergen Thiele, Daniel A Arber, Richard D Brunning, Michael J Borowitz, Anna Porwit, Nancy Lee Harris, Michelle M Le Beau, Eva Hellström-Lindberg, Ayalew Tefferi,[...]. Blood 2009
9

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
Tiziano Barbui, Ayalew Tefferi, Alessandro M Vannucchi, Francesco Passamonti, Richard T Silver, Ronald Hoffman, Srdan Verstovsek, Ruben Mesa, Jean-Jacques Kiladjian, Rȕdiger Hehlmann,[...]. Leukemia 2018
282
9

Age-related mutations associated with clonal hematopoietic expansion and malignancies.
Mingchao Xie, Charles Lu, Jiayin Wang, Michael D McLellan, Kimberly J Johnson, Michael C Wendl, Joshua F McMichael, Heather K Schmidt, Venkata Yellapantula, Christopher A Miller,[...]. Nat Med 2014
9

Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
Marito Araki, Yinjie Yang, Nami Masubuchi, Yumi Hironaka, Hiraku Takei, Soji Morishita, Yoshihisa Mizukami, Shin Kan, Shuichi Shirane, Yoko Edahiro,[...]. Blood 2016
176
9

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Claire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, Jean-Jacques Kiladjian, Ramon V Tiu, Pierre Zachee, Eric Jourdan, Elliott Winton, Richard T Silver, Harry C Schouten,[...]. Lancet Haematol 2017
176
9

Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.
Raajit Rampal, Fatima Al-Shahrour, Omar Abdel-Wahab, Jay P Patel, Jean-Philippe Brunel, Craig H Mermel, Adam J Bass, Jennifer Pretz, Jihae Ahn, Todd Hricik,[...]. Blood 2014
269
9


Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.
Priya Koppikar, Neha Bhagwat, Outi Kilpivaara, Taghi Manshouri, Mazhar Adli, Todd Hricik, Fan Liu, Lindsay M Saunders, Ann Mullally, Omar Abdel-Wahab,[...]. Nature 2012
257
8

Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera.
Ayalew Tefferi, Paola Guglielmelli, Terra L Lasho, Giacomo Coltro, Christy M Finke, Giuseppe G Loscocco, Benedetta Sordi, Natasha Szuber, Giada Rotunno, Annalisa Pacilli,[...]. Br J Haematol 2020
76
10

Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.
Ofir Wolach, Rob S Sellar, Kimberly Martinod, Deya Cherpokova, Marie McConkey, Ryan J Chappell, Alexander J Silver, Dylan Adams, Cecilia A Castellano, Rebekka K Schneider,[...]. Sci Transl Med 2018
204
8

Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms.
Debra Van Egeren, Javier Escabi, Maximilian Nguyen, Shichen Liu, Christopher R Reilly, Sachin Patel, Baransel Kamaz, Maria Kalyva, Daniel J DeAngelo, Ilene Galinsky,[...]. Cell Stem Cell 2021
65
12

Myeloproliferative neoplasm stem cells.
Adam J Mead, Ann Mullally. Blood 2017
87
9


Myeloproliferative Neoplasms: A Contemporary Review.
Ayalew Tefferi, Animesh Pardanani. JAMA Oncol 2015
197
8

Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice.
José J Fuster, Susan MacLauchlan, María A Zuriaga, Maya N Polackal, Allison C Ostriker, Raja Chakraborty, Chia-Ling Wu, Soichi Sano, Sujatha Muralidharan, Cristina Rius,[...]. Science 2017
681
8

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
Alfonso Quintás-Cardama, Kris Vaddi, Phillip Liu, Taghi Manshouri, Jun Li, Peggy A Scherle, Eian Caulder, Xiaoming Wen, Yanlong Li, Paul Waeltz,[...]. Blood 2010
555
7

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
Srdan Verstovsek, Hagop Kantarjian, Ruben A Mesa, Animesh D Pardanani, Jorge Cortes-Franco, Deborah A Thomas, Zeev Estrov, Jordan S Fridman, Edward C Bradley, Susan Erickson-Viitanen,[...]. N Engl J Med 2010
881
7

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.
Jean-Jacques Kiladjian, Bruno Cassinat, Sylvie Chevret, Pascal Turlure, Nathalie Cambier, Murielle Roussel, Sylvia Bellucci, Bernard Grandchamp, Christine Chomienne, Pierre Fenaux. Blood 2008
412
7

Mutations and prognosis in primary myelofibrosis.
A M Vannucchi, T L Lasho, P Guglielmelli, F Biamonte, A Pardanani, A Pereira, C Finke, J Score, N Gangat, C Mannarelli,[...]. Leukemia 2013
510
7

JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin.
Mark A Dawson, Andrew J Bannister, Berthold Göttgens, Samuel D Foster, Till Bartke, Anthony R Green, Tony Kouzarides. Nature 2009
436
7

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.
Srdan Verstovsek, Jason Gotlib, Ruben A Mesa, Alessandro M Vannucchi, Jean-Jacques Kiladjian, Francisco Cervantes, Claire N Harrison, Ronald Paquette, William Sun, Ahmad Naim,[...]. J Hematol Oncol 2017
146
7

Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.
Jacob Grinfeld, Jyoti Nangalia, Anthony R Green. Haematologica 2017
44
15

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
Maria Kleppe, Minsuk Kwak, Priya Koppikar, Markus Riester, Matthew Keller, Lennart Bastian, Todd Hricik, Neha Bhagwat, Anna Sophia McKenney, Efthymia Papalexi,[...]. Cancer Discov 2015
195
7



Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.
David P Steensma, Rafael Bejar, Siddhartha Jaiswal, R Coleman Lindsley, Mikkael A Sekeres, Robert P Hasserjian, Benjamin L Ebert. Blood 2015
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.